#USA #New York #Pomerantz LLP #SMMT #Summit Therapeutics

Pomerantz Law Firm Investigates Summit Therapeutics

Pomerantz LLP has initiated an investigation on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT), following substantial drops in the company's stock value. The firm is examining whether Summit and certain executives engaged in securities fraud or other unlawful business conduct.

During recent weeks, Summit faced significant setbacks. On May 30, 2025, the company released topline results from the Phase III clinical trial of its drug ivonescimab—a treatment designed to improve outcomes for patients with certain cancers. The trial indicated that patients receiving ivonescimab in conjunction with chemotherapy were 48% less likely to experience disease progression or death compared to those treated with chemotherapy alone. However, the drug did not result in a statistically significant improvement in overall survival rates, a critical measure that considers how long patients survived before passing away from any cause. As a direct consequence of this disappointing data, Summit's stock plummeted by $7.99, equating to a staggering 30.5% decrease, with shares closing at $18.22.

The situation worsened when, on September 7, 2025, additional data from the same trial revealed that ivonescimab performed poorly among patients from North America and Europe, compared to those from other regions. This news led to another significant dip, with shares dropping by $6.54, amounting to a 25.15% plunge, closing at $19.45 the following day.

As investors process these developments, Pomerantz LLP invites affected shareholders to reach out, emphasizing the importance of collective action in the face of corporate negligence. The firm's investigation is driven by a commitment to hold companies accountable for potential misconduct that may harm investors.

About Pomerantz LLP

Pomerantz LLP is a well-respected law firm recognized for its expertise in corporate, securities, and antitrust class litigation. Established over 85 years ago by Abraham L. Pomerantz, famously known as the dean of the class action bar, the firm has focused on the rights of investors, diligently fighting against fraud and breaches of fiduciary duty. Pomerantz has a rich history of recovering substantial damage awards on behalf of its clients, reflecting its dedication to justice and accountability in the financial sector.

Call to Action

Affected shareholders are encouraged to contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, ext. 7980. Joining the class action could be a pivotal step for investors seeking restitution in light of Summit Therapeutics’ recent challenges.

For more information on this investigation and class action participation, visit Pomerantz LLP's website.

In summary, the shares of Summit Therapeutics have faced increased volatility due to unexpected trial results, prompting serious inquiries into the company’s practices. As Pomerantz LLP steps in to investigate potential investor claims, the spotlight remains on the company's leadership and its handling of this critical situation.